Navigation Links
VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists
Date:2/13/2008

Could have impact on cancer treatment and other systemic uses of drugs to

target vascular endothelial growth factor (VEGF)

BOSTON, Feb. 13 /PRNewswire/ -- New research by scientists at Schepens Eye Research Institute may help explain why the anti-cancer drug Avastin, which targets a growth factor responsible for creation of new blood vessels, causes potentially fatal brain inflammation in certain patients. Institute scientists mimicked the drug's activity in mice and found that it damaged the cell lining that prevents fluid from leaking from the ventricle into the brain. The ventricle is the structure in the brain that holds cerebral spinal fluid after it is produced and which is continuous with the spinal cord. The results are currently published online (on February 11th) in The Journal of Experimental Medicine.

"This finding is significant because it may ultimately modify the way we use systemic drugs that block blood vessel growth, and it also suggests that VEGF (vascular endothelial growth factor) plays a more extensive role in the body than we previously thought," says Dr. Patricia D'Amore, senior scientist at Schepens Eye Research Institute and principal investigator of the study.

The cancer drug Avastin (bevacizumab) is used to treat advanced bowel cancer in combination with chemotherapy. By targeting VEGF, Avastin inhibits the growth of tumors by cutting off their blood supply and thus depriving them of oxygen and other nutrients. In a small percentage of patients, however, Avastin can cause neurological side effects, ranging from headaches and blurry vision to potentially fatal seizures and brain swelling.

D'Amore and her team found that VEGF normally protects the specialized cells that create a seal between the brain and ventricle and thus prevent fluid from leaking into the brain. When VEGF was blocked in mice, these cells were damaged and the animals developed brain lesions. The authors suspect that Avastin's side effects in humans may be caused by a similar phenomenon. Why these symptoms occur in only a few patients is not yet known.

Authors of the study include: Arindel S.R. Maharaj(2,3), Tony E. Walshe(2,3), Magali Saint-Geniez(2,3), Shivalingappa Venkatesha(2,4), Angel E. Maldonado (2,3), Nathan C. Himes(2), Kabir S. Matharu(3), S. Ananth Karumanchi(2,4) and Patricia A. D'Amore(1,2,3)

(1) Departments of Ophthalmology and Pathology

(2) Harvard Medical School

(3) Schepens Eye Research Institute

(4) Center for Vascular Biology, Departments of Medicine, Obstetrics,

Gynecology, Surgery and Pathology, Beth Israel

Deaconess Medical Center.

Schepens Eye Research Institute is an affiliate of Harvard Medical School and the largest independent eye research institute in the nation.


'/>"/>
SOURCE Schepens Eye Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VEGF neutralization can damage brain vessels, say Schepens Eye Research Institute scientists
2. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
3. Anti-cancer drug damages brain vessels
4. Novel compound may lessen heart attack damage
5. Gene predicts heart attack response and cardiac damage
6. Regular marijuana use increases risk of hepatitis C-related liver damage
7. Over-the-counter eardrops may cause hearing loss or damage
8. Over-the-counter eardrops may cause hearing loss or damage
9. Evolution of human genomes guardian gives people unique protections from DNA damage
10. Priming Heart Before an Attack Could Limit Damage
11. Genes identified that protect against heart damage from chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest Herbals will be phasing ... the popular ClearLungs Extra Strength formula. To ensure that the effectiveness of Clear Lungs ... ways:, , Removal of the homeopathic element , ...
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept that hearing aids ... doesn’t have the stigma it had when great-grandpa wore his hearing aids years ago,” ... a NALA North American Speaker Series (NASS) segment. “He probably wore an ...
Breaking Medicine News(10 mins):
(Date:4/25/2017)... April 25, 2017 Endo International plc (NASDAQ: ... 2017. Members of its senior management team will host a conference ... a.m. ET. The dial-in number to access the ... 509-7598, and the passcode is 6086379. Please dial in 10 minutes ... A replay of the call will be available from May ...
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
Breaking Medicine Technology: